Table 5 Plasma malondialdehyde concentration pre- and post-treatment in the control and treatment groups varying by stage in myxomatous mitral valve degenerative dogs
Control group (n = 11) | Plasma MDA (μg/mL) | |
Pre-treatment | Post-treatment | |
MMVD stage B2 (n = 5) | 4.59 ± 2.87 | 4.70 ± 1.26 |
MMVD stage C (n = 6) | 7.90 ± 3.30 | 7.06 ± 1.76 |
Treatment group (n = 17) | Plasma MDA (μg/mL) | |
Pre-treatment | Post-treatment | |
MMVD stage B2 (n = 6) | 7.84 ± 5.71 | 3.48 ± 2.01 |
MMVD stage C (n = 11) | 7.33 ± 4.22 | 5.05 ± 2.81 * |